Actinium Pharmaceuticals (API), a private biopharmaceutical company in New York that develops innovative targeted radio-immunotherapeutics, has strengthened its management team with the appointment of Jack V. Talley as president and CEO and Enza Guagenti as CFO.

Talley has more than 30 years of experience in marketing, drug development and regulatory matters. He is responsible for guiding two prior companies, Penwest Pharmaceuticals and EpiCept, through the transition to becoming public reporting entities, where until recently he served as president and CEO. Additionally, Talley oversaw the approval of Ceplene for the remission maintenance of acute myeloid leukemia in the E.U. as well as its license and eventual sale to Meda.

Guagenti is a CPA with over 25 years of experience in health care management financial oversight. Prior to assuming the role of CFO, she worked for API as a corporate accounting consultant for the past eight years. Guagenti has held senior management positions for various companies where she was responsible for operational and financial oversight and reporting, as well as compliance with state and federal regulatory bodies. Guagenti has also served on various state healthcare committees.